Brown & Brown (NYSE: BRO), an insurance broker, faces pressure as falling catastrophe-property rates cut commissions. First-half 2026 organic revenue fell 0.3%, though it rose 1.6% when contingent commissions from insurers are included. Contingent commissions, which depend largely on insurers' underwriting profits, have cushioned the decline. The company's Specialty Distribution division shrank 3.5% in the second quarter, while Retail grew 1.5%. The August 2025 acquisition of RSC Topco, Inc. lifted reported revenue 30.4%. Quarterly interest expense rose to $100 million from $51 million, and diluted shares increased to 334 million from 293 million. The stock trades at about 13x forward earnings, against 20x trailing. Rival Arthur J. Gallagher & Co. trades at about 16x, with faster expected earnings growth.

Brown & Brown shares are trading at a discount to the insurance brokerage industry, with a forward price-to-earnings ratio of 15.04X versus the industry average of 16.51X. The company has a market capitalisation of $23.96 billion. The stock has gained 27.4% over the past three months, outperforming the industry's 22.4% growth. Analysts' average price target of $76.44 suggests a potential 7.6% upside from recent levels. The Zacks Consensus Estimate projects 2026 earnings per share to increase 5.6% year-over-year, with revenues reaching $7.04 billion, up 19.2%. Growth is supported by increasing new business, strong client retention, and strategic acquisitions. The company's recent Accession acquisition contributed approximately $410 million to second-quarter 2026 revenues, with expected synergies of $30-$40 million in 2026.

Five insurance brokers stocks reported largely satisfactory Q2 earnings, with revenues beating analyst consensus estimates by 0.8% overall. Share prices have held steady, rising 2.1% on average since results were released. Brown & Brown reported revenues of $1.68 billion, up 30.4% year on year. However, this figure fell short of analyst expectations by 2.5%. Despite scoring the fastest revenue growth amongst peers, it had the weakest performance against analyst estimates. The stock has risen 2.7% since reporting and currently trades at $71.60. Ryan Specialty delivered the strongest Q2 performance, reporting revenues of $916.6 million, up 7.2% year on year and outperforming analyst expectations by 5.3%. The insurance brokerage industry benefits from rising risk complexity and regulatory scrutiny, though faces challenges from labour intensity and wage inflation.